Glioma-related mutations have been linked to this increased VTE risk – the incidence is strikingly higher in patients with isocitrate dehydrogenase 1 (IDH1) wildtype tumors, which distinguishes glioblastomas from other gliomas [38]. Here, IDH1 is linked to glioma.